NICE guidance (NG28) recommends that patients starting GLP-1 receptor agonists like Ozempic should have: Baseline assessment including HbA1c, renal function, and body weight Regular monitoring of glycaemic control and tolerability Review at 6 months to assess treatment response (defined as HbA1c reduction of at least 11 mmol/mol and weight loss of at least 3% of initial body weight) Ongoing assessment of cardiovascular risk factors Patients with pre-existing conditions require particular consideration
(%) de hemoglobina glucosilada -Cambio estimado desde el inicio al final del tratamiento en SUSTAIN 1-7, monoterapia japonesa y combinacin de HGO* Japn estudios (semaglutida gris oscuro de 0.5 mg, semaglutida 1 mg negro, tratamiento competidores blanco y placebo gris claro
"It's often more difficult for older folks to use injectables," says Jonathan H
Comprehensive Support Beyond the Injection We focus on lifestyle modification including nutrition guidance, exercise recommendations, sleep hygiene, and stress management
[DOI] [PubMed] [Google Scholar] Zhao W., Wang M., Wang L., Liu M., Jiang K., Xia S., et al
